β2-adrenoreceptor agonists, montelukast, and Parkinson's disease risk.

Bojing LiuPer SvenningssonJonas F LudvigssonCecilia LundholmJohan WallinHenrik LarssonArvid SjölanderDylan M WilliamsNancy L PedersenKarin Wirdefeldt

Published in: Annals of neurology (2023)

Overall, our data do not support inverse associations between β2AR agonists, montelukast, and PD. The prospect of lower PD incidence with high-dose montelukast exposure warrants further investigation, especially with adjustment for high quality data on smoking. This article is protected by copyright. All rights reserved.

Keyphrases

high dose
electronic health record
big data
low dose
risk factors
stem cell transplantation
machine learning
data analysis
current status